Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with a novel mechanism, inhibiting bacterial DNA replication at a distinct binding site. Phase 3 trials EAGLE-2 and EAGLE-3 showed ...

In a recent long-term, multicenter analysis of patients undergoing robot-assisted radical cystectomy, the 12-year overall survival for the entire cohort was 49%, whereas the cancer-specific survival ...

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, ...

"A lot of times…decreased desire is affected by everything else: pain with sex, orgasm, arousal. Because if none of that is good, then desire isn't going to be good either," says Anna Myers, CNP. In a ...

Aquablation and LEP provide similar short-term symptom relief for BPH, with Aquablation showing lower ejaculatory dysfunction and stress incontinence rates. LEP offers superior prostate volume ...

An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes ...

Durvalumab addition improved overall and event-free survival without affecting radical cystectomy rates or surgical complications in muscle-invasive bladder cancer. Surgical outcomes and ...

"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH. Nadofaragene firadenovec-vncg (Adstiladrin) was ...

Isodose MHFRT shows similar efficacy to CFRT without increased urinary or bowel toxicity, supporting its use as a standard care regimen. Dose-escalated MHFRT is associated with higher odds of bowel ...

“I think we can really use AI in several different facets of endourology," says Perry Xu, MD. In a recent interview with Urology Times®, Perry Xu, MD, spoke about artificial intelligence’s potential ...

The phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma. The phase 2 STARLITE 2 trial (NCT05239533) is assessing the safety and efficacy ...

Experts briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk non–muscle-invasive bladder cancer (NMIBC), and share their ...